Xbrane's Q2 PnL came in slightly ahead of our expectations, but the report reinforces the case's central risk: without an October FDA approv...
Xbrane's Q2 results came in ahead of our estimates on revenue and EBIT, but the report reinforces the case's central risk: without an Octobe...
Xbrane has partnered with California-based CDMO JOINN Biologics to advance CMC development of Xdarzane, its preclinical daratumumab biosimil...
The FDA has accepted Xbrane's BLA resubmission for Lucamzi and set a BsUFA action date of 29 October 2026, keeping potential US approval on ...
Xbrane delivered a quiet Q1, showing revenue of SEK17.
Xbrane's Q1 report showed a continued pressured outlook for Ximluci, with the volume growth in the quarter being negative.
Redeye updates on Xbrane following its year-end 2025 report showing softer revenue and a higher loss than our projections.
Xbrane's year-end report showed lower revenue, consisting almost exclusively of delieveries to STADA leading to a higher loss on the EBIT le...
Xbrane today provided an update on the expected timeline for the resubmission of the BLA for its ranibizumab biosimilar, indicating a planne...
Redeye provides an update on Xbrane following the Lucamzi CRL and its Q3 report.
Redeye anticipates a pronounced decline in Xbrane’s share at market open.
Redeye comments on Xbrane following yesterday’s press release, which provided updates on a conditional financing solution and the FDA re-ins...
Redeye updates its view on Xbrane following its Q2 report.
Redeye comments on Xbrane following its SEK240m directed share issue targeting both institutional and industrial capital.
Redeye updates its view on Xbrane following a stronger-than-expected Q1 report, with both revenue and EBIT exceeding estimates.
Redeye's provides its initial take on Xbrane's Q1 report which confirmed a stronger than anticipated sequential volume growth for Ximluci of...
Redeye provides an update on Xbrane following the recent deal with Alvotech, which has materially improved the company’s financial position,...
Redeye provides its initial take on Xbrane following the sale of its Cimzia biosimilar (XB003) and part of its organization to Alvotech.
Redeye provides an updated view on Xbrane following its year-end report, which showed continued growth in end-customer sales and signs of im...
Redeye’s comments on Xbrane following its year-end report, which showed negative revenue growth both y/y and q/q.
Redeye leaves a comment on Xbrane’s press release stating that it now has re-submitted its Lucentis biosimilar’s BLA to the FDA.
Redeye views Xbrane’s announcement of a partner for its Opdivo biosimilar as a positive development as it improves the company's financial p...
Redeye makes slight adjustments to its forecasts following Xbrane's Q3 report, which indicated continued growth in end-customer sales.
Redeye's comments on Xbrane following its Q3 report noted softer-than-expected results; however, the company continues to show sequential vo...
Redeye comments on Xbrane following today's news that the FDA, like the EMA, has recieved positive feedback for a streamlined development pl...
Redeye updates its view on Xbrane following a Q2 report hinting at accelerating sales but also highlighting a vulnerable financial position.
Redeye’s initial take on Xbrane’s Q2 report is that end-customer sales and profit split were higher than estimated.
Redeye leaves its initial take on Xbrane following this mornings news that Xbrane has regained the full rights to BIIB801 following Biogen's...
Redeye leaves its comments on today's press release from Xbrane confirming the succesful scale up of its Opdivo biosimilar Xdivane.
Redeye returns with a research update following Xbrane’s Q1 report.
Redeye leaves its initial comments on Xbrane's Q1 report, which came in softer than we had pencilled on both revenues and EBIT.
Redeye leave its comments on Xbrane following the announcement of a USD45m deal plus royalties for Xbrane's ranibizumab biosimilar on the US...
Redeye publishes a follow-up note subsequent to yesterday's conference call concerning sunday's CRL from the FDA.
Redeye provides its initial comments on yesterday evening’s news that Xbrane has received a CRL from the FDA related to its Ximluci BLA.
Redeye leaves a short comment on yesterday evenings news that Xbrane Biopharma has recieved additional subscription commitments to its right...
Redeye comments on Xbrane’s year-end report, updates its forecasts following recent developments, and adjusts its valuation for the rights i...
Redeye shares its initial view on Xbrane's year-end report, which was higher than anticiated on revenues but pretty much in line in terms of...
Redeye leave a comment on Xbrane following today's announcement of a SEK343m rights issue of units.
Redeye adjusts its estimates and fair value range for Xbrane Biopharma following its Q3 2023 report, which prompted a substantial decline in...
Redeye see a Q3 report from Xbrane that came in slightly above estimates in terms of revenues, but was softer than we had forecasted on the ...
Redeye considers Xbrane’s Q2 weak due to slower sales ramp-up than anticipated and postponed profitability.
Following today's unexpected news of the discontinued deal with Bausch + Lomb, Redeye is providing its comments on Xbrane.
Redeye positively views today's news that Xbrane's filing has been accepted by the FDA.
Redeye provides its view on Xbrane following its Q1 2023 report, which included the notable milestone of Ximluci’s first-ever sales.
Redeye positively views yesterday's press release, which included a SEK350m capital injection and the first preliminary sales figures from X...
Redeye reiterates its SEK173 base case following today’s announced Framework agreement with NHS and an eventful year ahead.
Redeye endorses today’s news that Xbrane has submitted its BLA to the FDA for its biosimilar candidate to Lucentis, which is already launche...
Redeye endorses today's press release announcing that Ximluci is now being launched by STADA and Xbrane in major European markets.
Redeye slightly adjusts its fair value range of Xbrane on the back of the Q4 report.
Redeye endorses that the MHRA has granted marketing authorization for Ximluci® in the UK.
Redeye leaves its comments on Xbrane following today's news that the re-submission to the FDA has been delayed from Q4 2022 to Q1 2023.
Redeye leaves a short comment on today’s news that Xbrane and STADA have secured EU approval for Ximluci.
Redeye remains positive on the investment case in Xbrane Biopharma following its Q3 2022 report.
Yesterday evening Xbrane carried out a directed share issue of SEK 170m to strengthen the balance sheet ahead of the forthcoming Q1 2023 lau...
Redeye feels encouraged following today’s positive CHMP opinion on Ximluci (Xlucane), marking a major milestone for the company and its part...
Redeye comments on Xbrane Biopharma’s Q2 2022 report, which despite the recent setback, leaves us feeling encouraged ahead of the European l...
Redeye leaves a short comment on today’s press release from Xbrane stating that the company intends to file a resubmission of its BLA for Xl...
Redeye leaves a more elaborate comment on yesterday morning's news that Xbrane has withdrawn its Xlucane submission to the FDA.
Redeye feels disappointed following FDA requesting complimentary information ahead of accepting the BLA for Xlucane.
Redeye leaves its view on Xbrane Biopharma following today’s Q1, confirming that a BLA submission to the FDA took place at the end of March.
Redeye returns with an updated assessment and a raised fair value range for Xbrane following the announced licensing deal with Biogen.
Following Monday's announcement of the Xcimzane licensing deal with Biogen, Redeye is convinced that Xbrane shares are currently trading at ...
Redeye reiterates its Base Case of SEK 167 following Xbrane’s Q2 report.
Redeye raises its valuation on Xbrane following the positive outcome of its phase III study Xplore.
